Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer

Meneguzzo, Alberto; Lazzarotto, Annalisa; Alaibac, Mauro

doi:10.21873/invivo.11793

Cited by 7 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism behind nevi involution with BRAFis is believed to be the presence of the BRAF V600E mutation in the nevi melanocytes, which increases their susceptibility to treatment with the later agents [ 9 ]. In addition, eruptive melanocytic nevi with vemurafenib or encorafenib have also been described [ 130 , 131 ]. The explanation for this phenomenon, as well as for an increase in nevi size and pigmentation, is attributed to a BRAFi-assοciated proliferation of wild-type BRAF cells in the melanocytic lesions due to the activation of the RAS-RAF-MEK-ERK pathway, which induces increased cell proliferation and survival [ 130 ].…”

Section: Braf-inhibitorsmentioning

confidence: 99%

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Plachouri

Florou

Georgiou

et al. 2023

Cancers

View full text Add to dashboard Cite

The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.

show abstract

Section: Braf-inhibitorsmentioning

confidence: 99%

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Plachouri

Florou

Georgiou

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, there has been one similar eruptive nevi case in a colorectal cancer patient treated with encorafenib and cetuximab. 4 The patient noted the development of nevi 2 months after starting encorafenib. In our case, nevi developed 3 days after encorafenib administration.…”

Section: E265mentioning

confidence: 99%

Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient

Omori

Miyagaki

Miyano³

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

“…Molecules 2019, 25, 1364 3 of 12 3: Encorafenib, for the oral treatment of skin cancer [21][22][23][24], and crizotinib [25][26][27], also taken orally and used in lung cancer. This review is organized into two sections.…”

Section: Pyrazole Alkaloids Found In Watermelon Seedsmentioning

confidence: 99%

“…It features anti-inflammatory properties in carrageenan-induced mice paw oedema [18], nephroprotecting action in cisplatin-induced mice kidney damage [19], and a caspase-mediated apoptotic effect on lung cancer cells (A549 line) [20]. The pyrazole core is also found in the structure of a few synthetic commercial drugs, such as the nonsteroidal anti-inflammatory agents celecoxib and lonazolac, and two antitumor drugs, represented in Figure 3: Encorafenib, for the oral treatment of skin cancer [21][22][23][24], and crizotinib [25][26][27], also taken orally and used in lung cancer. 3: Encorafenib, for the oral treatment of skin cancer [21][22][23][24], and crizotinib [25][26][27], also taken orally and used in lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Natural and Biomimetic Antitumor Pyrazoles, A Perspective

et al. 2020

View full text Add to dashboard Cite

The present review presents an overview of antitumor pyrazoles of natural or bioinspired origins. Pyrazole compounds are relatively rare in nature, the first ones having been reported in 1966 and being essentially used as somniferous drugs. Cytotoxic pyrazoles of natural sources were first isolated in 1969, and a few others have been reported since then, most of them in the last decade. This paper presents a perspective on the current knowledge on antitumor natural pyrazoles, organized into two sections. The first focuses on the three known families of cytotoxic pyrazoles that were directly isolated from plants, for which the knowledge of the medicinal properties is in its infancy. The second section describes pyrazole derivatives of natural products, discussing their structure–activity relationships.

show abstract

Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer

Cited by 7 publications

References 24 publications

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient

Natural and Biomimetic Antitumor Pyrazoles, A Perspective

Contact Info

Product

Resources

About